The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 317-326

  Becker, Marie N ^a   Wu, Kevin J ^b   Marlow, Laura A ^b   Kreinest, Pamela A ^b   vonRoemeling, Christina A ^b   Copland, John A ^b   Williams, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antitumor synergy; Bladder cancer; EGFR; Lapatinib; MTOR

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; P4EBPI PROTEIN; PAKT PROTEIN; PROTEIN; PS6 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TRIAZINE DERIVATIVE;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IC 50; IMMUNOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; PURINES; QUINAZOLINES; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TRIAZINES; URINARY BLADDER NEOPLASMS;

EID: 84897087742     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.002     Document Type: Article

References (31)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
3. Yafi F.A., Aprikian A.G., Chin J.L., Fradet Y., Izawa J., Estey E., et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2011, 108:539-545.
4. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
5. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
6. Park S.J., Lee T.J., Chang I.H. Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study. Korean J Urol 2011, 52:466-473.
7. Tickoo S.K., Milowsky M.I., Dhar N., Dudas M.E., Gallagher D.J., Al-Ahmadie H., et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int 2011, 107:844-849.
8. Makhlin I., Zhang J., Long C.J., Devarajan K., Zhou Y., Klein-Szanto A.J., et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011, 108:E84-E90.
9. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009;73: 665-8; [discussion 68-9].
10. Hansel D.E., Platt E., Orloff M., Harwalker J., Sethu S., Hicks J.L., et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010, 176:3062-3072.
11. Mansure J.J., Nassim R., Chevalier S., Rocha J., Scarlata E., Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009, 8:2339-2347.
12. Seager C.M., Puzio-Kuter A.M., Patel T., Jain S., Cordon-Cardo C., Mc Kiernan J., et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res 2009, 2:1008-1014.
13. Puzio-Kuter A.M., Castillo-Martin M., Kinkade C.W., Wang X., Shen T.H., Matos T., et al. Inactivation of p53 and PTEN promotes invasive bladder cancer. Genes Dev 2009, 23:675-680.
14. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORc1 and mTORc2. PLoS Biol 2009, 7:e38.
15. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., et al. Effective and selective targeting of leukemia cells using a TORc1/2 kinase inhibitor. Nat Med 2010, 16:205-213.
16. Bhagwat S.V., Gokhale P.C., Crew A.P., Cooke A., Yao Y., Mantis C., et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORc1 and mTORc2: distinct from rapamycin. Mol Cancer Ther 2011, 10:1394-1406.
17. Gupta M., Hendrickson A.E., Yun S.S., Han J.J., Schneider P.A., Koh B.D., et al. Dual mTORc1/mTORc2 inhibition diminishes AKT activation and induces PUMA-dependent apoptosis in lymphoid malignancies. Blood 2012, 119:476-487.
18. Grivas P.D., Day M., Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res 2011, 3:362-373.
19. Kramer C., Klasmeyer K., Bojar H., Schulz W.A., Ackermann R., Grimm M.O. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007, 109:2016-2024.
20. Lae M., Couturier J., Oudard S., Radvanyi F., Beuzeboc P., Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010, 21:815-819.
21. Wulfing C., Machiels J.P., Richel D.J., Grimm M.O., Treiber U., De Groot M.R., et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009, 115:2881-2890.
22. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011, 1:248-259.
23. Garcia-Garcia C., Ibrahim Y.H., Serra V., Calvo M.T., Guzman M., Grueso J., et al. Dual mTORc1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012, 18:2603-2612.
24. Cassell A., Freilino M.L., Lee J., Barr S., Wang L., Panahandeh M.C., et al. Targeting TORc1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012, 14:1005-1014.
25. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
26. Huang S., Yang Z.J., Yu C., Sinicrope F.A. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem 2011, 286:40002-40012.
27. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011, 25:460-470.
28. Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24:5218-5225.
29. Kompier L.C., Lurkin I., van der Aa M.N., van Rhijn B.W., van der Kwast T.H., Zwarthoff E.C. FGFR3, HRAS, KRAS, NRAS and PIK3ca mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010, 5:e13821.
30. Li X., Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hvps34 complex. Cancer Res 2010, 70:5942-5952.
31. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012, 12:401-410.